Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | FPR3 | P25089 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22276649 | 0.91 | PDK2 (0.40) | PDK2GBA1BLMPMP22HSD17B10 | |
| SCHEMBL22276510 | 0.91 | PDK2 (0.40) | PDK2GBA1BLMPMP22HSD17B10 | |
| SCHEMBL1040957 | 0.90 | PDK2 (0.39) | PDK2GBA1L3MBTL1CA14FPR3 | |
| SCHEMBL21107800 | 0.87 | PDK2 (0.36) | PDK2GBA1BLMPMP22HSD17B10 | |
| SCHEMBL12092269 | 0.87 | PDK2 (0.36) | PDK2GBA1BLMPMP22HSD17B10 | |
| SCHEMBL30380347 | 0.87 | PDK2 (0.36) | PDK2GBA1BLMPMP22HSD17B10 | |
| SCHEMBL15160779 | 0.87 | PDK2 (0.36) | PDK2GBA1BLMPMP22HSD17B10 | |
| SCHEMBL27382459 | 0.87 | PDK2 (0.36) | PDK2GBA1BLMPMP22HSD17B10 | |
| SCHEMBL21458670 | 0.85 | MEN1 (0.38) | PDK2GBA1BLMPMP22HSD17B10 | |
| SCHEMBL21107802 | 0.85 | MEN1 (0.38) | PDK2GBA1BLMPMP22HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | ARRAKIS THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | NSUN3, NSUN2, POLRMT | PDK2 2914/4885GBA1 254/4885BLM 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.